LATEST VERIFIED AI EXECUTION
Our quantitative model captured a massive +11.41% net profit on $TIP.MI in just 121h 17m. Stop guessing, start executing.
$HIK.L
Hikma Pharmaceuticals PLC
UNITED KINGDOMLAST 10 EARNINGS GAPS (%)
QUANTITATIVE LIVE RADAR BLOTTER
Institutional execution stream for $HIK.L
| Execution Date | Strategy & Setup | Direction | Execution Range | Hold Time | Exit Trigger | Net PnL |
|---|---|---|---|---|---|---|
| 2026-08-07 | QUANT ALGO | SELL x5 | $•••.•• → $•••.•• | 6m | 🔒 ENCRYPTED | -1.20% |
| ••••-••-•• | 🔒 LOCKED | ••• x• | $•••.•• → $•••.•• | ••h ••m | 🔒 LOCKED | +••.••% |
| ••••-••-•• | 🔒 LOCKED | ••• x• | $•••.•• → $•••.•• | ••h ••m | 🔒 LOCKED | +••.••% |
Exact execution prices, stop-loss triggers, and full trade logs are reserved for PRO members.
VOLATILITY & BIAS PROFILE
Intelligence Brief
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, and Rx. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Rx segment includes… Read full dossier